Related Experiment Videos
Drugs and cardiotoxicity in HIV and AIDS
M Fantoni1, C Autore, C Del Borgo
1Department of Infectious Diseases, Catholic University, Rome, Italy. crif@rm.unicatt.it
Insights
Highly active antiretroviral therapy (HAART) improves HIV outcomes but can cause adverse cardiac effects like hyperlipidemia and arrhythmias. Monitoring cardiac risk factors and drug interactions is crucial for long-term patient safety.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Highly active antiretroviral therapy (HAART) has significantly improved outcomes for HIV-infected patients.
- Long-term adverse effects of HAART, particularly cardiac complications, are a growing concern.
- Increased survival in HIV patients necessitates a focus on drug-related cardiac issues.
Purpose of the Study:
- To highlight the importance of recognizing and managing adverse drug-related cardiac effects in HIV-infected patients.
- To inform clinicians about potential cardiac risks associated with HAART and other medications used in HIV management.
- To emphasize the need for monitoring cardiovascular risk factors and drug interactions.
Main Methods:
- Review of known adverse effects of antiretroviral drugs, including protease inhibitors.
- Discussion of drug-induced hyperlipidemia, hyperglycemia, and lipodystrophy.
- Analysis of potential cardiac risks such as QT prolongation, torsade de pointe, and cardiotoxicity from specific drug classes (e.g., anthracyclines).
Main Results:
- HAART, especially with protease inhibitors, is associated with hyperlipidemia (up to 50% prevalence) and other metabolic disturbances.
- Certain drug classes used in HIV+ patients can cause QT prolongation and life-threatening arrhythmias.
- Protease inhibitors inhibit CYP3A, increasing the risk of dangerous drug interactions.
- Anthracyclines used for HIV-related neoplasms can cause significant cardiotoxicity.
Conclusions:
- Clinicians must be aware of the potential for serious cardiac adverse effects from HAART and co-administered drugs.
- Regular evaluation of traditional coronary risk factors, including lipid profiles, is recommended before and during HAART.
- Vigilance regarding drug interactions, particularly those involving the CYP3A pathway, is essential for preventing severe arrhythmias.
Abstract:
The advent of potent antiretroviral drugs in recent years has had an impressive impact on mortality and disease progression in HIV-infected patients, so that issues related to long-term effects of drugs are of growing importance. Hyperlipidemia, hyperglycemia, and lipodystrophy are increasingly described adverse effects of highly active antiretroviral therapy (HAART), in particular when protease inhibitors are used. Hyperlipidemia is strikingly associated with the use of most available protease inhibitors, with an estimated prevalence of up to 50%. Because of the short observation period and the small number of cardiovascular events, epidemiological evidence for an increased risk of coronary heart disease in HIV-infected patients treated with HAART is not adequate at present; however, it is likely that shortly more data will accumulate to quantify this risk. Before starting HAART and during treatment it is reasonable to evaluate all patients for traditional coronary risk factors, including lipid profile. Among the drugs that are currently used in HIV+ patients, antibacterials, antifungals, psychotropic drugs and anti-histamines have been associated with QT prolongation or torsade de pointe, a life-threatening ventricular arrhythmia. Among the risk factors that may precipitate an asymptomatic electrocardiographic abnormality into a dangerous arrhythmia is the concomitant use of drugs that share the CYP3A metabolic pathway. Since most protease inhibitors are potent inhibitors of CYP3A, clinicians should be aware of this potentially dangerous effect of HAART. Anthracyclines are potent cytotoxic antibiotics that have been widely used for the treatment of HIV-related neoplasms. Their cardiotoxicity is well known, ranging from benign and reversible arrhythmias to progressive severe cardiomyopathy. The increased survival and quality of life of HIV+ patients emphasize the importance of a high awareness of adverse drug-related cardiac effects.